PGM is pleased to announce the completion of the first patient in its IDE-approved clinical safety study for its Regenn™ Negative Pressure Therapy System.  “Placing the first Regenn™ NPTS device was an honor and I look forward to continuing to work with the Progenerative Medical team as the study progresses”, said the lead surgeon of the study.  CEO, Neal Vail, noted “obtaining human clinical data for Regenn™ NPTS is a significant milestone for the Company and continues to be our primary focus.”  PGM expects the safety study to be completed in 2026.  San Antonio, TX, USA. March 2025.